INCYTE CORP. news, videos and press releases
For more news please use our advanced search feature.
INCYTE CORP. - More news...
INCYTE CORP. - More news...
- Incyte to Report First Quarter Financial Results
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
- Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
- Incyte to Present at Upcoming Investor Conferences
- Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
- Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
- Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte to Present at Upcoming Investor Conference
- Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
- Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Incyte Announces Updated Presentation Time for Upcoming Investor Conference
- Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
- Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
- Incyte to Present at Upcoming Investor Conference
- CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
- Incyte to Present at Upcoming Investor Conferences
- Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
- Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
- Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
- Incyte to Report Second Quarter Financial Results
- MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
- Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
